SCHEMBL2534701

SCHEMBL2534701

COC(=O)c1ccc2nc(-n3cccn3)nc(N3CCOCC3)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
PIK3CA P42336 8/20 0.43
EGLN1 Q9GZT9 4/20 0.41
MTOR P42345 4/20 0.40
JAK3 P52333 1/20 0.40
NTRK2 Q16620 1/20 0.40
CAMK2A Q9UQM7 1/20 0.40
ALDH1A1 P00352 3/20 0.39
PIK3CD O00329 2/20 0.38
PIK3CG P48736 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
ALOX15 P16050 1/20 0.38
PIK3R1 P27986 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2530453 0.88 LMNA (0.52) LMNAHTTPIK3CAEGLN1MTOR
SCHEMBL2533823 0.83 HTT (0.46) LMNAHTTPIK3CAEGLN1MTOR
SCHEMBL2536578 0.82 CD38 (0.41) HTTPIK3CAMTORALDH1A1PIK3CD
SCHEMBL2531267 0.78 PIK3CA (0.54) LMNAHTTPIK3CAMTORALDH1A1
SCHEMBL2532500 0.74 LMNA (0.47) LMNAHTTPIK3CAEGLN1MTOR
SCHEMBL2534032 0.73 HTT (0.43) LMNAHTTPIK3CAEGLN1MTOR
SCHEMBL2532492 0.72 PIK3CA (0.57) LMNAHTTPIK3CAEGLN1MTOR
SCHEMBL13258235 0.71 PIK3CA (0.77) PIK3CAMTORALDH1A1PIK3CG
SCHEMBL2531932 0.71 CD38 (0.45) PIK3CAMTORPIK3CDPIK3CGPIK3R1
SCHEMBL1711450 0.71 LMNA (0.39) LMNAHTTPIK3CAEGLN1MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
WO-2010037765-A2 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO S.A. (CH) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES PIK3CA, PIK3CD, PIK3CG LMNA 4183/4885HTT 3933/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.